NEWS

Sensus Healthcare Installs First Groundbreaking SRT-100+ Superficial Radiation Therapy System for Treating Keloid Scars

Press Release



Dr. Kenrick Spence of Hillcrest Plastic Surgery in Orlando First to Offer System

BOCA RATON, Fla.Nov. 29, 2018 /PRNewswire/ — Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers (NMSC) and keloids with Image-Guided Superficial Radiation Therapy (IGSRT), has installed its first SRT-100+ system at Hillcrest Plastic Surgery in Orlando, Fla., specifically for the treatment of keloid scars. Earlier this year, Sensus received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its new SRT-100+, which adds several innovative features to Sensus’ existing SRT-100 product for non-melanoma skin cancer and keloid treatment.

Read the full press release here.

The Benefits of SRT

Along with eliminating the risks for post-surgical infections and complications, the SRT-100™ provides patients and physicians with a safe and effective treatment option that offers many benefits, including:

  1. 95%+ cure rates that rival surgery
  2. No anesthesia, cutting, bleeding, stitching or pain
  3. No downtime or lifestyle restrictions
  4. Super cosmesis, no unsightly scarring
  5. No need for post-treatment reconstructive surgeries